Acorda resubmits fampridine-SR for US approval in MS
This article was originally published in Scrip
Executive Summary
Acorda Therapeutics has resubmitted its NDA to the US FDA for its lead development candidate, the multiple sclerosis therapy, Fampridine-SR (4-aminopyridine), less than one month after receiving a refusal to file letter. Acorda is seeking an indication of improving patients' walking abilities when used in combination with other MS drugs.